Gilead signals steps to widen global access to remdesivir for Covid-19 patients

(By Ed Silverman for STAT)

Amid questions about access to remdesivir, its treatment for Covid-19, Gilead Sciences (GILD) says it is pursuing several steps, including licensing agreements with several unnamed companies, to ensure the medicine is supplied to countries beyond the U.S. Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.